Tu Y, Renfro LA. Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology. Ther Innov Regul Sci. 2024 Nov;58(6):1201-1213. doi: 10.1007/s43441-024-00698-3. Epub 2024 Sep 13. PMID: 39271644; PMCID: PMC11530510.
Study ID Citation
Abstract
As cancer has become better understood on the molecular level with the evolution of gene sequencing techniques, considerations for individualized therapy using predictive biomarkers (those associated with a treatment’s effect) have shifted to a new level. In the last decade or so, randomized “adaptive enrichment” clinical trials have become increasingly utilized to strike a balance between enrolling all patients with a given tumor type, versus enrolling only a subpopulation whose tumors are defined by a potential predictive biomarker related to the mechanism of action of the experimental therapy. In this review article, we review recent innovative design extensions and adaptations to adaptive enrichment designs proposed during the last few years in the clinical trial methodology literature, both from Bayesian and frequentist perspectives.